Accreditation/
Credit Designation
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Merck & Co., Inc. and Prometheus Laboratories Inc.11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
March 7, 2015
InterContinental Miami
100 Chopin Plaza
Miami, FL 33131
Phone: (305) 577-1000
Overview
The 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a one-day educational and scientific meeting that will focus on key clinical topics in the management of melanoma and other cutaneous malignancies, including evolving standards of care and current guidelines for chemotherapeutics, targeted agents, local and regional therapies, and immunotherapies, as well as the proper combinations and sequences of the most promising novel agents currently undergoing clinical trial evaluation. This highly practical and interactive forum will provide a unique opportunity for oncologists and other health care professionals to learn from and interact with leading national faculty in order to increase clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.Target Audience
This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.
Learning Objectives
At the conclusion of this activity, participants should be better prepared to:
- Choose treatment based on patient characteristics, such as age and performance status
- Assess the roles of regional therapies, targeted therapies, and immunotherapies in the treatment of patients
- Review strategies for mitigating and managing adverse events related to therapy
- Describe current and emerging strategies for individualizing therapy
- Evaluate emerging clinical data regarding new regional therapies, targeted therapies, and immunotherapies in treating melanoma and other cutaneous malignancies
Program Co-Chairs
Jeffrey S. Weber, MD, PhDSenior Member and Director
Donald A. Adam Comprehensive Melanoma Research Center
Moffitt Cancer Center
Tampa, FL
Omid Hamid, MDChief, Translational Research and Immunotherapy
Director, Melanoma Therapeutics
The Angeles Clinic and Research Institute
Keynote Speaker
Sam DonaldsonRegister
You must be logged in to PER to register for this meeting
Or Register for PER now
*Required Fields
Login Information
Registration Information
In case of onsite emergency:
Professional Information
Specialties*
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.
.jpg "PER")
